M&A Deal Summary |
|
---|---|
Date | 2020-06-24 |
Target | Tetraphase Pharmaceuticals |
Sector | Life Science |
Buyer(s) | La Jolla Pharmaceutical |
Deal Type | Going Private |
Deal Value | 43M USD |
Advisor(s) | Janney Montgomery Scott LLC (Financial) Wilmer Cutler Pickering Hale and Dorr (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1989 |
Sector | Life Science |
Revenue | 76M USD (2021) |
La Jolla Pharmaceutical is a biotechnology company involved in the development of therapeutics for lupus nephritis and other autoimmune diseases. La Jolla Pharmaceutical was founded in 1989 and is based in Waltham, Massachusetts.
DEAL STATS | # |
---|---|
Overall | 2 of 2 |
Sector (Life Science) | 1 of 1 |
Type (Going Private) | 1 of 1 |
State (Massachusetts) | 1 of 1 |
Country (United States) | 2 of 2 |
Year (2020) | 1 of 1 |
Size (of disclosed) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2012-01-19 |
Solana Therapeutics
San Diego, California, United States Solana Therapeutics, Inc. is a developer and manufacturer of drug GCS-100. |
Buy | - |